Bio-Rad - Preparing for a Stress-free QC Audit

Exothera to manufacture Meissa Vaccines’ paediatric RSV vaccine candidate for Phase 2 trials

Meissa Vaccines, a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, has entered into a manufacturing agreement with Exothera, a Univercells company and full-service Contract Research Development and Manufacturing Organization (CRDMO). Exothera delivers customized process development and GMP manufacturing services for vaccines, viral vectors and nucleic acids. Under the agreement, Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under Current Good Manufacturing Practice (CGMP) regulations to supply Phase 2 clinical trials. MV-012-968 is an intranasal live attenuated RSV vaccine in clinical development to protect infants and young children from respiratory syncytial virus (RSV).

Commenting on the development, Frank Glavin, Chief Executive Officer, Meissa Vaccines, said: “We are excited about our progress in advancing our paediatric RSV vaccine, and we are looking forward to working with Exothera on CGMP manufacturing of MV-012-968 for clinical supply. The clinical data we have generated from both our RSV and COVID-19 vaccine programmes demonstrate the enormous potential of Meissa’s ‘AttenuBlock’ platform to develop safe and effective intranasal live attenuated vaccines to protect against serious respiratory viruses, and we look forward to continuing to advance our vaccine candidates in Phase 2 clinical trials.”

Scherm­afbeelding 2023 09 13 om 10.30.05

Darren Leva, Chief Business Officer, Exothera commented: “We are excited to contribute to the development of such a promising paediatric vaccine against RSV and humbled that Meissa recognizes the value of our unique history of viral vector innovation and expertise to help manufacture their live attenuated RSV vaccine candidate for clinical use.”

At Exothera’s GMP state-of-the-art facility located in Jumet, Belgium, Exothera will manufacture Meissa’s MV-012-968 under cGMP regulations using the scale-X platform developed by Univercells. The scale-X platform is designed for high volume and highest quality production of vaccines with a small footprint.